AN2 Therapeutics, Inc. (ANTX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AN2 Therapeutics, Inc. has put a temporary hold on enrolling new patients in their Phase 3 trial for epetraborole, a drug aimed at treating a challenging lung condition known as MAC. This pause is to allow for a detailed analysis of Phase 2 data, which suggested the drug might be less effective than hoped, although no safety issues triggered the decision. While the review is underway, the existing patients will continue their treatments, and the company is set to release Phase 2 results in the upcoming summer. The outcome of the review could lead to modifications in the study’s protocol for the next phase.
For further insights into ANTX stock, check out TipRanks’ Stock Analysis page.